Generic drugs account for approximately 90% of all prescriptions dispensed in the United States, yet they represent only about 18% […]

Drug patent abandonment is not a clerical failure. It is a calculated move within a broader lifecycle management strategy or

The contract development and manufacturing organization industry crossed $238 billion in global market value in 2024. By 2032, analysts project

The U.S. generic drug market saves $445 billion a year. It also fails, systematically and predictably, to keep the most

1. What a Generic Drug Actually Is, Legally and Commercially The Regulatory Definition and Why It Is a Legal Construct,

A field-by-field breakdown of 15 structural flaws that put pharmaceutical IP strategy at risk There is a particular kind of

The emerging market pharmaceutical story has a simple headline: $500 billion by 2027, compounding at roughly 6.9% annually. What that

Part 1: The Market Reality Behind Analytical Similarity The Patent Cliff Driving a $185 Billion Opportunity The global biosimilar market

A deep-dive for pharma/biotech IP counsel, formulary directors, health economics leads, and institutional investors The Scale of the Problem: Spending